Sientra, Inc.

Good day and welcome to the Cientra Incorporated fourth quarter and full year 2022 earnings conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to your host, Mr. Oliver Bennett, Cientra's General Counsel and Chief Compliance Officer. Mr. Bennett, you may begin. Thank you. Good afternoon.

we are pleased that you could join us on today's call to discuss Cientra's fourth quarter and full year 2022 financial results and business update. On our call today, we have Ron Menezes, Cientra's President and Chief Executive Officer, Andy Schmidt, Cientra's Chief Financial Officer, Lisa Rosas, Cientra's Senior Vice President of Marketing, and Dr. Denise Giles, Cientra's Senior Vice President of Research and Development, Regulatory and Quality. As reported earlier today, we have achieved another record quarter and year for Cientra. Our Q4 revenue of $25.1 million is the highest quarterly revenue in the history of the company and represents almost 100% growth in our breast product business from our pre-pandemic high of $12.8 million in Q4 2019. While we see continued strength in our core implant and expander portfolio, We have also taken steps to accelerate our growth with the commercial launch of our biology fat transfer system and our recently announced partnership with the Zio Biologics. As Juan will provide more detail on, these new products dramatically increase our total addressable market to over $1 billion in the United States alone, while also enhancing our pathway to profitability. Of course, I must remind everyone that in our remarks today, we will include forward-looking statements in our prepared remarks and response to any questions you may ask. These forward-looking statements are based on management's current assumptions and expectations of future events and trends. Our actual results may differ materially from those expressed in or implied by the forward-looking statements. The company undertakes no obligation to update or review any estimate, projection, or forward-looking statements. For more detailed discussion of the company's risks and uncertainties, I would refer you to our SEC filings, including our Form 10-K and Form 10-Q available on the company's website. With that, I'll turn the call over to our President and Chief Executive Officer, Ron, to comment on our continued exemplary growth this past quarter and provide a look ahead at 2023 and beyond.

Two and a half years ago, in the middle of the pandemic, I stepped into my role as CEO of Cientra. At that time, the management team and I redefined Cientra's corporate mission. We set the goal to create an all-inclusive platform that will deliver innovative solutions to plastic surgeons within the broader aesthetic community. Today, I'm pleased to report that not only we are well on our way to meeting that goal, but also that this year will be a transformational year for Cientra. Our management team has made a concerted effort to invest on our infrastructure. Our goal was to create a platform to enable new products to flow through our organization, creating leverage and paving the path to profitability. We are now seeing the results of those efforts come to fruition. First, we'll commence commercial shipping of our Violet fat transfer system on March 1st. Second, as we announced last week, who have entered into a partnership with Azeo Biologics to add their Simple Derm, a cellular dermal matrix product, to our portfolio. The addition of those products dramatically increases Centra's total addressable market, with the ADM market alone estimated to be around $500 million. Both products are highly synergistic for Centra, allowing us to use our existing sales and distribution teams with no significant capital investments. We believe the addition of those highly complementary products will not only accelerate our market share gains and overall growth, but also enhance our pathway to profitability by creating leverage on our existing organization. 22 ended strong for Sandra. With those year-end operational results, the first shipments of Viality, and SimpleDerm joining our portfolio, I am pleased to report today that we expect to make our path to profitability and positive free cash flow a reality by year end 2023. We'll continue to follow a successful corporate strategy this year, which emphasizes the following. One, streamlining resources and time towards the interest of high growth, high margin business. And two, focusing every team on increasing operating efficiencies. The critical steps it took in 22 sets the pathway for 23 to be a transformational year for Cientra. I'll now turn the call over to Lisa Rosas, our SVP for marketing.